Charged particle radiation therapy

Information

  • Patent Grant
  • 7728311
  • Patent Number
    7,728,311
  • Date Filed
    Friday, November 17, 2006
    17 years ago
  • Date Issued
    Tuesday, June 1, 2010
    14 years ago
Abstract
Among other things, an accelerator is mounted on a gantry to enable the accelerator to move through a range of positions around a patient on a patient support. The accelerator is configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range. The proton or ion beam passes essentially directly from the accelerator to the patient. In some examples, the synchrocyclotron has a superconducting electromagnetic structure that generates a field strength of at least 6 Tesla, produces a beam of particles having an energy level of at least 150 MeV, has a volume no larger than 4.5 cubic meters, and has a weight less than 30 Tons.
Description
BACKGROUND

This description relates to charged particle (e.g., proton or ion) radiation therapy.


The energy of a proton or ion beam for therapy needs to be high compared to the energy of an electron beam used in conventional radiotherapy. A proton beam, for example, that has a residual range of about 32 cm in water is considered adequate to treat any tumor target in the human population. When allowance is made for the reduction in residual range that results from scattering foils used to spread the beam, an initial proton beam energy of 250 MeV is needed to achieve the residual range of 32 cm.


Several kinds of particle accelerators can be used to produce a 250 MeV proton beam at a sufficient beam current (e.g., about 10 nA) for radiotherapy, including linear accelerators, synchrotrons, and cyclotrons.


The design of a proton or ion radiation therapy system for a clinical environment should take account of overall size, cost, and complexity. Available space is usually limited in crowded clinical environments. Lower cost allows more systems to be deployed to reach a broader patient population. Less complexity reduces operating costs and makes the system more reliable for routine clinical use.


Other considerations also bear on the design of such a therapy system. By configuring the system to apply the treatment to patients who are held in a stable, reproducible position (for example, lying supine on a flat table), the physician can more precisely relocate the intended target, relative to the patient's anatomy, at each treatment. Reliable reproduction of the patient's position for each treatment also can be aided using custom molds and braces fitted to the patient. With a patient in a stable, fixed position, the radiotherapy beam can be directed into the patient from a succession of angles, so that, over the course of the treatment, the radiation dose at the target is enhanced while the extraneous radiation dose is spread over non-target tissues.


Traditionally, an isocentric gantry is rotated around the supine patient to direct the radiation beam along successive paths that lie at a range of angles in a common vertical plane toward a single point (called an isocenter) within the patient. By rotating the table on which the patient lies around a vertical axis, the beam can be directed into the patient along different paths. Other techniques have been used to vary the position of the radiation source around the patient, including robotic manipulation. And other ways to move or reposition the patient have been used.


In high energy x-ray beam therapy, the x-ray beam may be directed toward the isocenter from an electron linear accelerator mounted on the gantry or robotic arm.


In typical proton beam therapy, the circular particle accelerator that produces the beam is too large to mount on the gantry. Instead, the accelerator is mounted in a fixed position and the particle beam is redirected through a rotating gantry using magnetic beam steering elements. Blosser has proposed to mount an accelerator on the side of the gantry near the horizontal axis of rotation.


SUMMARY

In general, in one aspect, an accelerator is mounted on a gantry to enable the accelerator to move through a range of positions around a patient on a patient support. The accelerator is configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range. The proton or ion beam passes essentially directly from the accelerator housing to the patient.


Implementations may include one or more of the following features. The gantry is supported for rotation on bearings on two sides of the patient support. The gantry has two legs extending from an axis of rotation and a truss between the two legs on which the accelerator is mounted. The gantry is constrained to rotate within a range of positions that is smaller than 360 degrees, at least as large as 180 degrees and in some implementations in the range from about 180 degrees to about 330 degrees. (A rotation range of 180 degrees is sufficient to provide for all angles of approach into a supine patient.) Radio-protective walls include at least one wall that is not in line with the proton or ion beam from the accelerator in any of the positions within the range; that wall is constructed to provide the same radio-protection with less mass. The patient support is mounted in an area that is accessible through a space defined by a range of positions at which the gantry is constrained not to rotate. The patient support is movable relative to the gantry including rotation about a patient axis of rotation that is vertical. The patient axis of rotation contains an isocenter in the vicinity of a patient on the patient support. The gantry axis of rotation is horizontal and contains the isocenter. The accelerator weighs less than 40 Tons and in typical implementations within a range from 5 to 30 tons, occupies a volume of less than 4.5 cubic meters and typically in a range from 0.7 to 4.5 cubic meters, and produces a proton or ion beam having an energy level of at least 150 MeV and in a range from 150 to 300 MeV, for example 250 MeV.


The accelerator can be a synchrocyclotron with a magnet structure that has a field strength of at least 6 Tesla and can be from 6 to 20 Tesla. The magnet structure includes superconducting windings that are cooled by cryo-coolers. The proton or ion beam passes directly from the accelerator to the general area of the patient stand. A shielding chamber containing the patient support, the gantry, and the accelerator includes at least one wall of the chamber being thinner than other walls of the chamber. A portion of the chamber can be embedded within the earth.


In general, in one aspect, an accelerator is configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in a patient. The accelerator is small enough and lightweight enough to be mounted on a rotatable gantry in an orientation to permit the proton or ion beam to pass essentially directly from the accelerator housing to the patient.


In general, in one aspect, a medical synchrocyclotron has a superconducting electromagnetic structure that generates a field strength of at least 6 Tesla, produces a beam of particles, such as protons, having an energy level of at least 150 MeV, has a volume no larger than 4.5 cubic meters, and has a weight less than 30 Tons.


In general, in one aspect, a patient is supported within a treatment space, a beam of proton or ions pass in a straight line direction from an output of an accelerator to any arbitrary target within the patient, and the straight line direction is caused to be varied through a range of directions around the patient.


In general, in an aspect, a structure includes a patient support and a gantry on which an accelerator is mounted to enable the accelerator to move through a range of positions around a patient on the patient support. The accelerator is configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range. A walled enclosure contains the patient support, the gantry, and the accelerator. In some examples, more than half of the surface of the walled enclosure is embedded within the earth.


Other aspects include other combinations of the aspects and features discussed above and other features expressed as apparatus, systems, methods, software products, business methods, and in other ways.


By generating a magnetic field of about 10 Tesla, the size of the accelerator approaches 1.5 meter and the mass is reduced to about 15 to 20 tons. The weight will depend on the stray magnetic field that is to be allowed near the accelerator. Even smaller weights and sizes may be possible. This enables the cyclotron to be placed on a gantry, with the output beam aimed directly at the isocenter, and rotated around the patient, thus simplifying the delivery of proton or ion beam radiation therapy. All extracted beam focusing and steering elements are incorporated into the accelerator or immediately adjacent to it. The direct mounting of the accelerator on the gantry eliminates beam transport elements that would otherwise be required to transport the beam from the accelerator to the target volume within the patient. The size, complexity and cost of a proton or ion beam therapy system are reduced and its performance is improved. Reducing the range of rotation of the gantry to be less than 360 degrees in the vertical plane reduces the thickness of the shielding barrier that must be provided at locations to which the beam is never directed. It also allows for ease of access to the patient treatment space. The synchrocyclotron can be scaled to arbitrarily high fields without compromising beam focusing during acceleration. The elimination of cryogenic liquid cooled coils reduces the risk to the operator and the patient if vaporized liquid cryogen were to be released during a fault condition such as a magnet quench.


Other advantages and features will become apparent from the following description and from the claims.





DESCRIPTION OF DRAWINGS


FIG. 1 is a perspective view of a therapy system.



FIG. 2 is an exploded perspective view of components of a synchrocyclotron.



FIGS. 3, 4, and 5 are cross-sectional views of a synchrocyclotron.



FIG. 6 is a perspective view of a synchrocyclotron.



FIG. 7 is a cross-sectional view of a portion of a reverse bobbin and windings.



FIG. 8 is a cross sectional view of a cable-in-channel composite conductor.



FIG. 9 is a cross-sectional view of an ion source.



FIG. 10 is a perspective view of a dee plate and a dummy dee.



FIG. 11 is a perspective view of a vault.



FIG. 12 is a perspective view of a treatment room with a vault.



FIG. 13 shows a profile of one-half of a symmetrical profile of a pole face and a pole piece.





DETAILED DESCRIPTION

As shown in FIG. 1, a charged particle radiation therapy system 500 includes a beam-producing particle accelerator 502 having a weight and size small enough to permit it to be mounted on a rotating gantry 504 with its output directed straight (that is, essentially directly) from the accelerator housing toward a patient 506. The size and cost of the therapy system are significantly reduced and the reliability and precision of the system may be increased.


In some implementations, the steel gantry has two legs 508, 510 mounted for rotation on two respective bearings 512, 514 that lie on opposite sides of the patient. The accelerator is supported by a steel truss 516 that is long enough to span a treatment area 518 in which the patient lies (e.g., twice as long as a tall person, to permit the person to be rotated fully within the space with any desired target area of the patient remaining in the line of the beam) and is attached stably at both ends to the rotating legs of the gantry.


In some examples, the rotation of the gantry is limited to a range 520 of less than 360 degrees, e.g., about 180 degrees, to permit a floor 522 to extend from a wall of the vault 524 that houses the therapy system into the patient treatment area. The limited rotation range of the gantry also reduces the required thickness of some of the walls (which never directly receive the beam, e.g., wall 530) which provide radiation shielding of people outside the treatment area. A range of 180 degrees of gantry rotation is enough to cover all treatment approach angles, but providing a larger range of travel can be useful. For example the range of rotation may usefully be between 180 and 330 degrees and still provide clearance for the therapy floor space. When the range of travel is large, the gantry may swing to positions that are hazardous to people or equipment positioned in a portion of the therapy space.


The horizontal rotational axis 532 of the gantry is located nominally one meter above the floor where the patient and therapist interact with the therapy system. This floor is positioned about 3 meters above the bottom floor of the therapy system shielded vault. The accelerator can swing under the raised floor for delivery of treatment beams from below the rotational axis. The patient couch moves and rotates in a substantially horizontal plane parallel to the rotational axis of the gantry. The couch can rotate through a range 534 of about 270 degrees in the horizontal plane with this configuration. This combination of gantry and patient rotational ranges and degrees of freedom allow the therapist to select virtually any approach angle for the beam. If needed, the patient can be placed on the couch in the opposite orientation and then all possible angles can be used.


In some implementations, the accelerator uses a synchrocyclotron configuration having a very high magnetic field superconducting electromagnetic structure. Because the bend radius of a charged particle of a given kinetic energy is reduced in direct proportion to an increase in the magnetic field applied to it, the very high magnetic field superconducting magnetic structure permits the accelerator to be made smaller and lighter.


For an average magnetic field strength larger than about 5 Tesla, an isochronous cyclotron (in which the magnet is constructed to make the magnetic field stronger near the circumference than at the center to compensate for the mass increase and maintain a constant frequency of revolution) is impractical to use to achieve 250 MeV protons. This is because the angular variation in magnetic field used to maintain the beam focus in the isochronous cyclotron cannot be made large enough using iron pole face shaping.


The accelerator described here is a synchrocyclotron. The synchrocyclotron uses a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. Such a field shape can be achieved regardless of the magnitude of the magnetic field, so in theory there is no upper limit to the magnetic field strength (and therefore the resulting particle energy at a fixed radius) that can be used in a synchrocyclotron.


Certain superconducting materials begin to lose their superconducting properties in the presence of very high magnetic fields. High performance superconducting wire windings are used to allow very high magnetic fields to be achieved.


Superconducting materials typically need to be cooled to low temperatures for their superconducting properties to be realized. In some examples described here, cryo-coolers are used to bring the superconducting coil windings to temperatures near absolute zero. Using cryo-coolers, rather than bath cooling the windings in liquid Helium, reduces complexity and cost.


The synchrocyclotron is supported on the gantry so that the beam is generated directly in line with the patient. The gantry permits rotation of the cyclotron about a horizontal rotational axis that contains a point (isocenter 540) within or near the patient. The split truss that is parallel to the rotational axis, supports the cyclotron on both sides.


Because the rotational range of the gantry is limited, a patient support area can be accommodated in a wide area around the isocenter. Because the floor can be extended broadly around the isocenter, a patient support table can be positioned to move relative to and to rotate about a vertical axis 542 through the isocenter so that, by a combination of gantry rotation and table motion and rotation, any angle of beam direction into any part of the patient can be achieved. The two gantry arms are separated by more than twice the height of a tall patient, allowing the couch with patient to rotate and translate in a horizontal plane above the raised floor.


Limiting the gantry rotation angle allows for a reduction in the thickness of at least one of the walls surrounding the treatment room. Thick walls, typically constructed of concrete, provide radiation protection to individuals outside the treatment room. A wall downstream of a stopping proton beam needs to be about twice as thick as a wall at the opposite end of the room to provide an equivalent level of protection. Limiting the range of gantry rotation enables the treatment room to be sited below earth grade on three sides while allowing an occupied area adjacent to the thinnest wall reducing the cost of constructing the treatment room.


In the example implementation shown in FIG. 1, the superconducting synchrocyclotron 502 operates with a peak magnetic field in a pole gap of the synchrocyclotron of 8.8 Tesla. The synchrocyclotron produces a beam of protons having an energy of 250 MeV. In other implementations the field strength could be in the range of 6 to 20 Tesla and the proton energy could be in the range of 150 to 300 MeV


The radiation therapy system described in this example is used for proton radiation therapy, but the same principles and details can be applied in analogous systems for use in heavy ion (ion) treatment systems.


As shown in FIGS. 2, 3, 4, 5, and 6, an example synchrocyclotron 10 (502 in FIG. 1) includes a magnet system 12 that contains an ion source 90, a radiofrequency drive system 91, and a beam extraction system 38. The magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of a split pair of annular superconducting coils 40, 42 and a pair of shaped ferromagnetic (e.g., low carbon steel) pole faces 44, 46.


The two superconducting magnet coils are centered on a common axis 47 and are spaced apart along the axis. As shown in FIGS. 7 and 8, the coils are formed by of Nb3Sn-based superconducting 0.6 mm diameter strands 48 (that initially comprise a niobium-tin core surrounded by a copper sheath) deployed in a Rutherford cable-in-channel conductor geometry. After six individual strands are laid in a copper channel 50, they are heated to cause a reaction that forms the final (brittle) material of the winding. After the material has been reacted, the wires are soldered into the copper channel (outer dimensions 3.02×1.96 mm and inner dimensions 2.05×1.27 mm) and covered with insulation 52 (in this example, a woven fiberglass material). The copper channel containing the wires 53 is then wound in a coil having a rectangular cross-section of 6.0 cm×15.25 cm, having 30 layers and 47 turns per layer. The wound coil is then vacuum impregnated with an epoxy compound 54. The finished coils are mounted on an annular stainless steel reverse bobbin 56. A heater blanket 55 is held against the inner face of the bobbin and the windings to protect the assembly in the event of a magnet quench. In an alternate version the superconducting coil may be formed of 0.8 mm diameter Nb3Sn based strands. These strands can be deployed in a 4 strand cable, heat treated to form the superconducting matrix and soldered into a copper channel of outer dimension 3.19 by 2.57 mm. The integrated cable in channel conductor can be insulated with overlapped woven fiberglass tape and then wound into coils of 49 turns and 26 layers deep with a rectangular cross section of 79.79 mm by 180.5 mm and inner radius of 374.65 mm. The wound coil is then vacuum impregnated with an epoxy compound. The entire coil can then be covered with copper sheets to provide thermal conductivity and mechanical stability and then contained in an additional layer of epoxy. The precompression of the coil can be provided by heating the stainless steel reverse bobbin and fitting the coils within the reverse bobbin. The reverse bobbin inner diameter is chosen so that when the entire mass is cooled to 4 K, the reverse bobbin stays in contact with the coil and provides some compression. Heating the stainless steel reverse bobbin to approximately 50 degrees C. and fitting coils at room temperature (20 degrees C.) can achieve this.


The geometry of the coil is maintained by mounting the coils in a “reverse” rectangular bobbin 56 and incorporating a pre-compression stainless steel bladder 58 between each coil and an inner face 57 of the bobbin to exert a restorative force 60 that works against the distorting force produced when the coils are energized. The bladder is pre-compressed after the coils and the heater blanket are assembled on the bobbin, by injecting epoxy into the bladder and allowing it to harden. The precompression force of the bladder is set to minimize the strain in the brittle Nb3Sn superconducting matrix through all phases of cool-down and magnet energizing.


As shown in FIG. 5, the coil position is maintained relative to the magnet yoke and cryostat using a set of warm-to-cold support straps 402, 404, 406. Supporting the cold mass with thin straps minimizes the heat leakage imparted to the cold mass by the rigid support system. The straps are arranged to withstand the varying gravitational force on the coil as the magnet rotates on board the gantry. They withstand the combined effects of gravity and the large de-centering force realized by the coil when it is perturbed from a perfectly symmetric position relative to the magnet yoke. Additionally the links act to minimize the dynamic forces imparted on the coil as the gantry accelerates and decelerates when the position is changed. Each warm-to-cold support includes 3 S2 fiberglass links. Two links 410, 412 are supported across pins between the warm yoke and an intermediate temperature (50-70 K), and one link 408 is supported across the intermediate temperature pin and a pin attached to the cold mass. Each link is 10.2 cm long (pin center to pin center) and is 20 mm wide. The link thickness is 1.59 mm. Each pin is made of stainless steel and is 47.7 mm in diameter.


As shown in FIG. 13, the field strength profile as a function of radius is determined largely by choice of coil geometry; the pole faces 44, 46 of the permeable yoke material can be contoured to fine tune the shape of the magnetic field to insure that the particle beam remains focused during acceleration.


The superconducting coils are maintained at temperatures near absolute zero (e.g., about 4 degrees Kelvin) by enclosing the coil assembly (the coils and the bobbin) inside an evacuated annular aluminum or stainless steel cryostatic chamber 70 that provides a free space around the coil structure, except at a limited set of support points 71, 73. In an alternate version the outer wall of the cryostat may be made of low carbon steel to provide an additional return flux path for the magnetic field. The temperature near absolute zero is achieved and maintained using two Gifford-McMahon cryo-coolers 72, 74 that are arranged at different positions on the coil assembly. Each cryo-cooler has a cold end 76 in contact with the coil assembly. The cryo-cooler heads 78 are supplied with compressed Helium from a compressor 80. Two other Gifford-McMahon cryo-coolers 77, 79 are arranged to cool high temperature (e.g., 60-80 degrees Kelvin) leads 81 that supply current to the superconducting windings.


The coil assembly and cryostatic chambers are mounted within and fully enclosed by two halves 81, 83 of a pillbox-shaped magnet yoke 82. In this example, the inner diameter of the coil assembly is about 140 cm. The iron yoke 82 provides a path for the return magnetic field flux 84 and magnetically shields the volume 86 between the pole faces 44, 46 to prevent external magnetic influences from perturbing the shape of the magnetic field within that volume. The yoke also serves to decrease the stray magnetic field in the vicinity of the accelerator.


As shown in FIGS. 3 and 9, the synchrocyclotron includes an ion source 90 of a Penning ion gauge geometry located near the geometric center 92 of the magnet structure 82. The ion source is fed from a supply 99 of hydrogen through a gas line 101 and tube 194 that delivers gaseous hydrogen. Electric cables 94 carry an electric current from a current source 95 to stimulate electron discharge from cathodes 192, 194 that are aligned with the magnetic field, 200.


The discharged electrons ionize the gas exiting through a small hole from tube 194 to create a supply of positive ions (protons) for acceleration by one semicircular (dee-shaped) radio-frequency plate 100 that spans half of the space enclosed by the magnet structure and one dummy dee plate 102. As shown in FIG. 10, the dee plate 100 is a hollow metal structure that has two semicircular surfaces 103, 105 that enclose a space 107 in which the protons are accelerated during half of their rotation around the space enclosed by the magnet structure. A duct 109 opening into the space 107 extends through the yoke to an external location from which a vacuum pump 111 can be attached to evacuate the space 107 and the rest of the space within a vacuum chamber 119 in which the acceleration takes place. The dummy dee 102 comprises a rectangular metal ring that is spaced near to the exposed rim of the dee plate. The dummy dee is grounded to the vacuum chamber and magnet yoke. The dee plate 100 is driven by a radio-frequency signal that is applied at the end of a radio-frequency transmission line to impart an electric field in the space 107. The radiofrequency electric field is made to vary in time as the accelerated particle beam increases in distance from the geometric center. Examples of radio frequency waveform generators that are useful for this purpose are described in U.S. patent application Ser. No. 11/187,633,titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005,and in U.S. provisional patent application Ser. 60/590,089, same title, filed on Jul. 21, 2004,both of which are incorporated in their entirety by this reference.


For the beam emerging from the centrally located ion source to clear the ion source structure as it begins to spiral outward, a large voltage difference is required across the radiofrequency plates. 20,000 Volts is applied across the radiofrequency plates. In some versions from 8,000 to 20,000 Volts may be applied across the radiofrequency plates. To reduce the power required to drive this large voltage, the magnet structure is arranged to reduce the capacitance between the radio frequency plates and ground. This is done by forming holes with sufficient clearance from the radiofrequency structures through the outer yoke and the cryostat housing and making sufficient space between the magnet pole faces.


The high voltage alternating potential that drives the dee plate has a frequency that is swept downward during the accelerating cycle to account for the increasing relativistic mass of the protons and the decreasing magnetic field. The dummy dee does not require a hollow semi-cylindrical structure as it is at ground potential along with the vacuum chamber walls. Other plate arrangements could be used such as more than one pair of accelerating electrodes driven with different electrical phases or multiples of the fundamental frequency. The RF structure can be tuned to keep the Q high during the required frequency sweep by using, for example, a rotating capacitor having intermeshing rotating and stationary blades. During each meshing of the blades, the capacitance increases, thus lowering the resonant frequency of the RF structure. The blades can be shaped to create a precise frequency sweep required. A drive motor for the rotating condenser can be phase locked to the RF generator for precise control. One bunch of particles is accelerated during each meshing of the blades of the rotating condenser.


The vacuum chamber 119 in which the acceleration occurs is a generally cylindrical container that is thinner in the center and thicker at the rim. The vacuum chamber encloses the RF plates and the ion source and is evacuated by the vacuum pump 111. Maintaining a high vacuum insures that accelerating ions are not lost to collisions with gas molecules and enables the RF voltage to be kept at a higher level without arcing to ground.


Protons traverse a generally spiral path beginning at the ion source. In half of each loop of the spiral path, the protons gain energy as they pass through the RF electric field in space 107. As the ions gain energy, the radius of the central orbit of each successive loop of their spiral path is larger than the prior loop until the loop radius reaches the maximum radius of the pole face. At that location a magnetic and electric field perturbation directs ions into an area where the magnetic field rapidly decreases, and the ions depart the area of the high magnetic field and are directed through an evacuated tube 38 to exit the yoke of the cyclotron. The ions exiting the cyclotron will tend to disperse as they enter the area of markedly decreased magnetic field that exists in the room around the cyclotron. Beam shaping elements 107, 109 in the extraction channel 38 redirect the ions so that they stay in a straight beam of limited spatial extent.


The magnetic field within the pole gap needs to have certain properties to maintain the beam within the evacuated chamber as it accelerates. The magnetic field index

n=−(r/B)dB/dr


must be kept positive to maintain this “weak” focusing. Here r is the radius of the beam and B is the magnetic field. Additionally the field index needs to be maintained below 0.2,because at this value the periodicity of radial oscillations and vertical oscillations of the beam coincide in a νr=2 νZ resonance. The betatron frequencies are defined by νr=(1−n)1/2 and νZ=n1/2 The ferromagnetic pole face is designed to shape the magnetic field generated by the coils so that the field index n is maintained positive and less than 0.2 in the smallest diameter consistent with a 250 MeV beam in the given magnetic field.


As the beam exits the extraction channel it is passed through a beam formation system 125 that can be programmably controlled to create a desired combination of scattering angle and range modulation for the beam. Examples of beam forming systems useful for that purpose are described in U.S. patent application Ser. No. 10/949,734,titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004,and U.S. provisional patent application Ser. 60/590,088,filed Jul. 21, 2005,both of which are incorporated in their entirety by this reference.


During operation, the plates absorb energy from the applied radio frequency field as a result of conductive resistance along the surfaces of the plates. This energy appears as heat and is removed from the plates using water cooling lines 108 that release the heat in a heat exchanger 113.


Stray magnetic fields exiting from the cyclotron are limited by both the pillbox magnet yoke (which also serves as a shield) and a separate magnetic shield 114. The separate magnetic shield includes of a layer 117 of ferromagnetic material (e.g., steel or iron) that encloses the pillbox yoke, separated by a space 116. This configuration that includes a sandwich of a yoke, a space, and a shield achieves adequate shielding for a given leakage magnetic field at lower weight.


As mentioned, the gantry allows the synchrocyclotron to be rotated about the horizontal rotational axis 532. The truss structure 516 has two generally parallel spans 580, 582. The synchrocyclotron is cradled between the spans about midway between the legs. The gantry is balanced for rotation about the bearings using counterweights 122, 124 mounted on ends of the legs opposite the truss.


The gantry is driven to rotate by an electric motor mounted to one of the gantry legs and connected to the bearing housings by drive gears and belts or chains. The rotational position of the gantry is derived from signals provided by shaft angle encoders incorporated into the gantry drive motors and the drive gears.


At the location at which the ion beam exits the cyclotron, the beam formation system 125 acts on the ion beam to give it properties suitable for patient treatment. For example, the beam may be spread and its depth of penetration varied to provide uniform radiation across a given target volume. The beam formation system can include passive scattering elements as well as active scanning elements.


All of the active systems of the synchrocyclotron (the current driven superconducting coils, the RF-driven plates, the vacuum pumps for the vacuum acceleration chamber and for the superconducting coil cooling chamber, the current driven ion source, the hydrogen gas source, and the RF plate coolers, for example), are controlled by appropriate synchrocyclotron control electronics (not shown).


The control of the gantry, the patient support, the active beam shaping elements, and the synchrocyclotron to perform a therapy session is achieved by appropriate therapy control electronics (not shown).


As shown in FIGS. 1, 11, and 12, the gantry bearings are supported by the walls of a cyclotron vault 524. The gantry enables the cyclotron to be swung through a range 520 of 180 degrees (or more) including positions above, to the side of, and below the patient. The vault is tall enough to clear the gantry at the top and bottom extremes of its motion. A maze 146 sided by walls 148, 150 provides an entry and exit route for therapists and patients. Because at least one wall 152 is never in line with the proton beam directly from the cyclotron, it can be made relatively thin and still perform its shielding function. The other three side walls 154, 156, 150/148 of the room, which may need to be more heavily shielded, can be buried within an earthen hill (not shown). The required thickness of walls 154, 156, and 158 can be reduced, because the earth can itself provide some of the needed shielding.


For safety and aesthetic reasons, a therapy room 160 is constructed within the vault. The therapy room is cantilevered from walls 154, 156, 150 and the base 162 of the containing room into the space between the gantry legs in a manner that clears the swinging gantry and also maximizes the extent of the floor space 164 of the therapy room. Periodic servicing of the accelerator can be accomplished in the space below the raised floor. When the accelerator is rotated to the down position on the gantry, full access to the accelerator is possible in a space separate from the treatment area. Power supplies, cooling equipment, vacuum pumps and other support equipment can be located under the raised floor in this separate space.


Within the treatment room, the patient support 170 can be mounted in a variety of ways that permit the support to be raised and lowered and the patient to be rotated and moved to a variety of positions and orientations.


Additional information concerning the design of the accelerator can be found in U.S. provisional application Ser. No. 60/760,788,entitled HIGH-FIELD SUPERCONDUCTING SYNCHROCYCLOTRON (T. Antaya), filed Jan. 20, 2006, and U.S. patent application Ser. No. 11/463,402,entitled MAGNET STRUCTURE FOR PARTICLE ACCELERATION (T. Antaya, et al.), filed Aug. 9, 2006,and U.S. provisional application Ser. No. 60/850,565, entitled CRYOGENIC VACUUM BREAK PNEUMATIC THERMAL COUPLER (Radovinsky et al.), filed Oct. 10, 2006, all of which are incorporated in their entireties by reference here.


Other implementations are within the scope of the following claims.

Claims
  • 1. An apparatus comprising a patient support, anda gantry on which an accelerator is mounted to enable the accelerator to move through a range of positions around a patient on the patient support,the accelerator being configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range,the proton or ion beam passing essentially directly from an accelerator housing to the patient.
  • 2. The apparatus of claim 1 in which the gantry is supported for rotation on two sides of the patient support.
  • 3. The apparatus of claim 2 in which the gantry is supported for rotation on bearings on the two sides of the patient support.
  • 4. The apparatus of claim 1 in which the gantry comprises two arms extending from an axis of rotation of the gantry and a truss between the two arms on which the accelerator is mounted.
  • 5. The apparatus of claim 1 in which the gantry is constrained to rotate within a range of positions that is smaller than 360 degrees.
  • 6. The apparatus of claim 5 in which the range is at least as large as 180 degrees.
  • 7. The apparatus of claim 5 in which the range is from about 180 degrees to about 330 degrees.
  • 8. The apparatus of claim 5 also including radio-protective walls, at least one of which is not in line with the proton or ion beam from the accelerator in any of the positions within the range, the one wall being constructed to provide the same radio-protection than the other walls with less mass.
  • 9. The apparatus of claim 5 in which the patient support is mounted on a patient support area that is accessible through a space defined by a range of positions at which the gantry is constrained from rotation.
  • 10. The apparatus of claim 1 in which the patient support is movable relative to the gantry.
  • 11. The apparatus of claim 10 in which the patient support is configured for rotation about a patient axis of rotation.
  • 12. The apparatus of claim 11 in which the patient axis of rotation is vertical.
  • 13. The apparatus of claim 11 in which the patient axis of rotation contains an isocenter in a patient on the patient support.
  • 14. The apparatus of claim 1 in which the patient gantry is configured for rotation of the accelerator about a gantry axis of rotation.
  • 15. The apparatus of claim 14 in which the gantry axis of rotation is horizontal.
  • 16. The apparatus of claim 14 in which the axis of rotation contains an isocenter in a patient on the patient support.
  • 17. The apparatus of claim 1 in which the accelerator weighs less than 40 Tons.
  • 18. The apparatus of claim 17 in which the accelerator weighs in a range from 5 to 30 Tons.
  • 19. The apparatus of claim 1 in which the accelerator occupies a volume of less than 4.5 cubic meters.
  • 20. The apparatus of claim 19 in which the volume is in the range of 0.7 to 4.5 cubic meters.
  • 21. The apparatus of claim 1 in which the accelerator produces a proton or ion beam having an energy level of at least 150 MeV.
  • 22. The apparatus of claim 21 in which the energy level is in the range from 150 to 300 MeV.
  • 23. The apparatus of claim 1 in which the accelerator comprising a synchrocyclotron.
  • 24. The apparatus of claim 1 in which the accelerator comprises a magnet structure having a field strength of at least 6 Tesla.
  • 25. The apparatus of claim 24 in which the field strength is in the range of 6 to 20 Tesla.
  • 26. The apparatus of claim 24 in which the magnet structure comprises superconducting windings.
  • 27. The apparatus of claim 1 in which the proton or ion beam passes directly from the accelerator to the general area of the patient stand.
  • 28. The apparatus of claim 1 also including a shielding chamber containing the patient support, the gantry, and the accelerator, at least one wall of the chamber being thinner than other walls of the chamber.
  • 29. The apparatus of claim 28 in which at least a portion of the chamber is embedded within the earth.
  • 30. An apparatus comprising a medical synchrocyclotron having a superconducting electromagnetic structure that generates a field strength of at least 6 Tesla, produces, for delivery to a patient, a beam of charged particles having an energy level of at least 150 MeV, has a volume no larger than 4.5 cubic meters, and has a weight less than 30 Tons.
  • 31. An apparatus comprising an accelerator configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in a patient, the accelerator being small enough and lightweight enough to be mounted on a rotatable gantry in an orientation to permit the proton or ion beam to pass essentially directly from the accelerator to the patient.
  • 32. The apparatus of claim 31 in which the accelerator comprises a superconducting synchrocyclotron.
  • 33. A structure comprising a patient support;a gantry on which an accelerator is mounted to enable the accelerator to move through a range of positions around a patient on the patient support, the range of positions exceeding 180 degrees around the patient;the accelerator being configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range; anda walled enclosure containing the patient support, the gantry, and the accelerator.
  • 34. An apparatus comprising: a patient support; anda gantry on which an accelerator is mounted, the gantry being supported on two sides of the patient support for rotation (a) about a horizontal gantry axis that contains an isocenter in the patient and (b) through a range of positions that exceeds 180 degrees;the patient support being rotatable about a vertical patient support axis that contains the isocenter;the accelerator comprising a synchrocyclotron configured to produce a proton or ion beam having an energy level of at least 150 MeV to reach any arbitrary target in the patient directly from positions within the range, the synchrocyclotron having superconducting windings.
  • 35. A method comprising supporting a patient within a treatment space;causing a beam of proton or ions to pass in a straight line direction from an output of an accelerator to any arbitrary target within the patient; andcausing the straight line direction to be varied through a range of positions around the patient, the range of positions exceeding 180 degrees around the patient.
  • 36. An apparatus comprising an accelerator configured to produce a charged particle beam and to be mounted on a gantry that enables the accelerator to move through a range of positions around a patient on a patient support, the range of positions exceeding 180 degrees around the patient;the accelerator being configured to produce a charged particle beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range.
  • 37. An apparatus comprising a gantry configured to hold an accelerator and to enable the accelerator to move through a range of positions around a patient on a patient support, the range of positions exceeding 180 degrees around the patient; andthe accelerator being configured to produce a proton or ion beam having an energy level sufficient to reach any arbitrary target in the patient from positions within the range.
  • 38. The apparatus of claim 32 in which the magnetic field of the superconducting synchrocyclotron is in the range of 6 to 20 Tesla.
  • 39. The apparatus of claim 33 in which more than half of the surface of the walled enclosure is embedded within the earth.
Parent Case Info

This application is entitled to the benefit of the filing date of U.S. provisional patent application Ser. No. 60/738,404, filed Nov. 18, 2005, the entire text of which is incorporated by reference here.

US Referenced Citations (181)
Number Name Date Kind
2615129 McMillan Oct 1952 A
3175131 Burleigh et al. Mar 1965 A
3432721 Naydan et al. Mar 1969 A
3679899 Dimeff Jul 1972 A
3689847 Verster Sep 1972 A
3868522 Bigham et al. Feb 1975 A
3925676 Bigham et al. Dec 1975 A
3958327 Marancik et al. May 1976 A
3992625 Schmidt et al. Nov 1976 A
4038622 Purcell Jul 1977 A
4047068 Ress et al. Sep 1977 A
4112306 Nunan Sep 1978 A
4129784 Tschunt et al. Dec 1978 A
4139777 Rautenbach Feb 1979 A
4197510 Szu Apr 1980 A
4220866 Symmons et al. Sep 1980 A
4336505 Meyer Jun 1982 A
4345210 Tran Aug 1982 A
4353033 Kurasawa Oct 1982 A
4507614 Prono et al. Mar 1985 A
4507616 Blosser et al. Mar 1985 A
4589126 Augustsson et al. May 1986 A
4633125 Blosser et al. Dec 1986 A
4641057 Blosser et al. Feb 1987 A
4641104 Blosser et al. Feb 1987 A
4680565 Jahnke Jul 1987 A
4705955 Mileikowsky Nov 1987 A
4710722 Jahnke Dec 1987 A
4726046 Nunan Feb 1988 A
4734653 Jahnke Mar 1988 A
4737727 Yamada et al. Apr 1988 A
4739173 Blosser et al. Apr 1988 A
4745367 Dustmann et al. May 1988 A
4754147 Maughan et al. Jun 1988 A
4769623 Marsing et al. Sep 1988 A
4771208 Jongen et al. Sep 1988 A
4783634 Yamamoto et al. Nov 1988 A
4808941 Marsing Feb 1989 A
4812658 Koehler Mar 1989 A
4843333 Marsing et al. Jun 1989 A
4865284 Gosis et al. Sep 1989 A
4868843 Nunan Sep 1989 A
4868844 Nunan Sep 1989 A
4870287 Cole et al. Sep 1989 A
4880985 Jones Nov 1989 A
4902993 Krevent Feb 1990 A
4904949 Wilson Feb 1990 A
4905267 Miller et al. Feb 1990 A
4917344 Prechter et al. Apr 1990 A
4943781 Wilson et al. Jul 1990 A
4987309 Klasen et al. Jan 1991 A
4996496 Kitamura et al. Feb 1991 A
5017789 Young et al. May 1991 A
5017882 Finlan May 1991 A
5036290 Sonobe et al. Jul 1991 A
5039057 Prechter et al. Aug 1991 A
5039867 Nishihara et al. Aug 1991 A
5072123 Johnsen Dec 1991 A
5111173 Matsuda et al. May 1992 A
5117194 Nakanishi et al. May 1992 A
5117212 Yamamoto et al. May 1992 A
5117829 Miller et al. Jun 1992 A
5166531 Huntzinger Nov 1992 A
5189687 Bova et al. Feb 1993 A
5240218 Dye Aug 1993 A
5260581 Lesyna et al. Nov 1993 A
5278533 Kawaguchi Jan 1994 A
5317164 Kurokawa May 1994 A
5336891 Crewe Aug 1994 A
5341104 Anton et al. Aug 1994 A
5349198 Takanaka Sep 1994 A
5365742 Boffito et al. Nov 1994 A
5374913 Pissantezky et al. Dec 1994 A
5382914 Hamm et al. Jan 1995 A
5405235 Lebre et al. Apr 1995 A
5440133 Moyers et al. Aug 1995 A
5461773 Kawaguchi Oct 1995 A
5463291 Carroll et al. Oct 1995 A
5511549 Legg et al. Apr 1996 A
5521469 Laisne May 1996 A
5585642 Britton et al. Dec 1996 A
5668371 Deasy et al. Sep 1997 A
5726448 Smith et al. Mar 1998 A
5778047 Mansfield et al. Jul 1998 A
5811944 Sampayan et al. Sep 1998 A
5818058 Nakanishi et al. Oct 1998 A
5821705 Caporaso et al. Oct 1998 A
5825845 Blair et al. Oct 1998 A
5841237 Alton Nov 1998 A
5846043 Spath Dec 1998 A
5851182 Sahadevan Dec 1998 A
5866912 Slater et al. Feb 1999 A
5874811 Finlan et al. Feb 1999 A
5895926 Britton et al. Apr 1999 A
5920601 Nigg et al. Jul 1999 A
5929458 Nemezawa et al. Jul 1999 A
5993373 Nonaka et al. Nov 1999 A
6034377 Pu Mar 2000 A
6057655 Jongen May 2000 A
6061426 Linders et al. May 2000 A
6094760 Nonaka et al. Aug 2000 A
6265837 Akiyama et al. Jul 2001 B1
6268610 Pu Jul 2001 B1
6278239 Caporaso et al. Aug 2001 B1
6279579 Riaziat et al. Aug 2001 B1
6316776 Hiramoto et al. Nov 2001 B1
6433336 Jongen et al. Aug 2002 B1
6433349 Akiyama et al. Aug 2002 B2
6441569 Janzow Aug 2002 B1
6443349 Van Der Burg Sep 2002 B1
6476403 Dolinskii et al. Nov 2002 B1
6492922 New Dec 2002 B1
6501981 Schweikard et al. Dec 2002 B1
6621889 Mostafavi Sep 2003 B1
6683318 Haberer et al. Jan 2004 B1
6683426 Kleeven Jan 2004 B1
6693283 Eickhoff et al. Feb 2004 B2
6710362 Kraft et al. Mar 2004 B2
6717162 Jongen Apr 2004 B1
6769806 Moyers Aug 2004 B2
6774383 Norimine et al. Aug 2004 B2
6777700 Yanagisawa et al. Aug 2004 B2
6800866 Amemiya et al. Oct 2004 B2
6803591 Muramatsu et al. Oct 2004 B2
6814694 Pedroni Nov 2004 B1
6891177 Kraft et al. May 2005 B1
6914396 Symons et al. Jul 2005 B1
7014361 Ein-Gal Mar 2006 B1
7026636 Yanagisawa et al. Apr 2006 B2
7173385 Caporaso et al. Feb 2007 B2
7208748 Sliski et al. Apr 2007 B2
7348579 Pedroni Mar 2008 B2
7402963 Sliski Jul 2008 B2
7466085 Nutt Dec 2008 B2
7476883 Nutt Jan 2009 B2
20030048080 Amemiya et al. Mar 2003 A1
20030152197 Moyers Aug 2003 A1
20030163015 Yanagisawa et al. Aug 2003 A1
20030183779 Norimine et al. Oct 2003 A1
20030234369 Glukhoy Dec 2003 A1
20040000650 Yanagisawa et al. Jan 2004 A1
20040056212 Yanagisawa et al. Mar 2004 A1
20040061077 Muramatsu et al. Apr 2004 A1
20040061078 Muramatsu et al. Apr 2004 A1
20040085023 Chistyakov May 2004 A1
20040098445 Baumann et al. May 2004 A1
20040111134 Muramatsu et al. Jun 2004 A1
20040118081 Reimoser et al. Jun 2004 A1
20040149934 Yanagisawa et al. Aug 2004 A1
20040173763 Moriyama et al. Sep 2004 A1
20040174958 Moriyama et al. Sep 2004 A1
20040183033 Moriyama et al. Sep 2004 A1
20040183035 Yanagisawa et al. Sep 2004 A1
20040200982 Moriyama et al. Oct 2004 A1
20040200983 Fujimaki et al. Oct 2004 A1
20040213381 Harada Oct 2004 A1
20040227104 Matsuda et al. Nov 2004 A1
20040232356 Norimine et al. Nov 2004 A1
20040240626 Moyers Dec 2004 A1
20050089141 Brown Apr 2005 A1
20050161618 Eros Jul 2005 A1
20050184686 Caporaso et al. Aug 2005 A1
20050228255 Saracen et al. Oct 2005 A1
20050234327 Saracen et al. Oct 2005 A1
20050247890 Norimine et al. Nov 2005 A1
20060126792 Li Jun 2006 A1
20060284562 Hruby et al. Dec 2006 A1
20070001128 Sliski et al. Jan 2007 A1
20070013273 Albert et al. Jan 2007 A1
20070014654 Haverfield et al. Jan 2007 A1
20070023699 Yamashita et al. Feb 2007 A1
20070092812 Caporaso et al. Apr 2007 A1
20070145916 Caporaso et al. Jun 2007 A1
20070171015 Antaya Jul 2007 A1
20070181519 Khoshnevis Aug 2007 A1
20080093567 Gall Apr 2008 A1
20080218102 Sliski Sep 2008 A1
20090096179 Stark et al. Apr 2009 A1
20090140671 O'Neal, III et al. Jun 2009 A1
20090140672 Gall et al. Jun 2009 A1
20090200483 Gall et al. Aug 2009 A1
Foreign Referenced Citations (103)
Number Date Country
2753397 Jun 1978 DE
31 48 100 Jun 1983 DE
3530446 Aug 1984 DE
41 01 094 May 1992 DE
4411171 Oct 1995 DE
0194728 Sep 1986 EP
0 277 521 Aug 1988 EP
0208163 Jan 1989 EP
0222786 Jul 1990 EP
0221987 Jan 1991 EP
0499253 Aug 1992 EP
0 306 966 Apr 1995 EP
0 388 123 May 1995 EP
0 465 597 May 1997 EP
0 864 337 Sep 1998 EP
0 776 595 Dec 1998 EP
1 069 809 Jan 2001 EP
1 153 398 Apr 2001 EP
1 294 445 Mar 2003 EP
1 348 465 Oct 2003 EP
1 358 908 Nov 2003 EP
1 371 390 Dec 2003 EP
1 402 923 Mar 2004 EP
0 911 064 Jun 2004 EP
1 430 932 Jun 2004 EP
1430932 Jun 2004 EP
1 454 653 Sep 2004 EP
1 454 654 Sep 2004 EP
1 454 655 Sep 2004 EP
1 454 656 Sep 2004 EP
1 454 657 Sep 2004 EP
1 477 206 Nov 2004 EP
1 605 742 Dec 2005 EP
1738798 Jan 2007 EP
1826778 Aug 2007 EP
1949404 Jul 2008 EP
2 560 421 Aug 1985 FR
2911843 Aug 2008 FR
957342 May 1964 GB
2015821 Sep 1979 GB
2 361 523 Oct 2001 GB
43-23267 Oct 1968 JP
61-80800 Apr 1986 JP
62-150804 Jul 1987 JP
62-186500 Aug 1987 JP
63-149344 Jun 1988 JP
63-218200 Sep 1988 JP
63-226899 Sep 1988 JP
1-276797 Nov 1989 JP
4-94198 Mar 1992 JP
04-128717 Apr 1992 JP
04-129768 Apr 1992 JP
04-273409 Sep 1992 JP
04-337300 Nov 1992 JP
05-341352 Dec 1993 JP
06233831 Aug 1994 JP
06233831 Aug 1994 JP
06-036893 Oct 1994 JP
2007-260939 Oct 1995 JP
07260939 Oct 1995 JP
08-173890 Jul 1996 JP
08-264298 Oct 1996 JP
09-162585 Jun 1997 JP
10-071213 Mar 1998 JP
11-47287 Feb 1999 JP
11-102800 Apr 1999 JP
11-243295 Sep 1999 JP
2000-294399 Oct 2000 JP
2001-6900 Jan 2001 JP
2001-129103 May 2001 JP
2002-164686 Jun 2002 JP
2009-515671 Apr 2009 JP
300137 Nov 1969 SU
569 635 Aug 1977 SU
200930160 Jul 2009 TW
200934682 Aug 2009 TW
200939908 Sep 2009 TW
200940120 Oct 2009 TW
WO 8607229 Dec 1986 WO
WO90012413 Oct 1990 WO
WO 9203028 Feb 1992 WO
WO 9302536 Feb 1993 WO
WO 9817342 Apr 1998 WO
WO9939385 Aug 1999 WO
WO 0040064 Jul 2000 WO
WO 0049624 Aug 2000 WO
WO 0126569 Apr 2001 WO
WO 0207817 Jan 2002 WO
WO 03039212 May 2003 WO
WO 03092812 Nov 2003 WO
WO 2004026401 Apr 2004 WO
WO 2004101070 Nov 2004 WO
WO2007061937 May 2007 WO
WO 2007061937 May 2007 WO
WO2007084701 Jul 2007 WO
WO2007130164 Nov 2007 WO
WO2007145906 Dec 2007 WO
WO2008030911 Mar 2008 WO
WO 2009048745 Apr 2009 WO
WO2009-070173 Jun 2009 WO
WO2009-070588 Jun 2009 WO
WO2009-073480 Jun 2009 WO
WO 2009048745 Nov 2009 WO
Related Publications (1)
Number Date Country
20080093567 A1 Apr 2008 US
Provisional Applications (1)
Number Date Country
60738404 Nov 2005 US